NCT05372926

Brief Summary

in this study, the investigators aim to describe the effects of highflow nasal canulae oxygen therapy (HFNC) on respiratory muscle function during exercise in patients with fibrosing interstitial lung diseases (ILD) during an endurance test

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 13, 2022

Completed
6 months until next milestone

Study Start

First participant enrolled

November 22, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2024

Completed
Last Updated

November 23, 2022

Status Verified

November 1, 2022

Enrollment Period

2 years

First QC Date

April 6, 2022

Last Update Submit

November 22, 2022

Conditions

Keywords

interstitial lung diseasenasal high flow oxygen therapyendurance testpulmonary rehabilitation

Outcome Measures

Primary Outcomes (1)

  • Ptdi swing

    To compare the change in transdiaphragmatic pressure between baseline and peak during inspiration (Ptdi swing) between HFNC and VM in patients with fibrosing Interstitial Lung Disease in stable state, at isotime.

    during the intervention, at isotime

Secondary Outcomes (7)

  • PTPdi

    during the intervention, at isotime

  • PTPoeso

    during the intervention, at isotime

  • Poeso swing

    during the intervention, at isotime

  • DeltaPtdi/DeltaEAdi

    during the intervention, at isotime

  • SmO2

    during the intervention, at isotime

  • +2 more secondary outcomes

Study Arms (2)

Venturi mask

EXPERIMENTAL

Patients will be placed under oxygen therapy with Venturi mask at a constant flow of 15L/min and a set FiO2 of 50%. The real FiO2 will be mesured in the mask at rest.

Device: Ventury mask

High flow nasal canulae

EXPERIMENTAL

Patients will be placed under high flow nasal canulae oxygen therapy with a constant flow of 50L/min and the real FiO2 provided by Venturi mask.

Device: high flow nasal canulae

Interventions

high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.

High flow nasal canulae

Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.

Venturi mask

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cared for as part of a respiratory rehabilitation program (ADIR association)
  • Presenting diffuse fibrosing interstitial pneumonitis, documented by CT scan data and whatever its etiology
  • Presenting severe hypoxemia in ambient air (SpO2\<90%) during an exercise test (6-minute walk test or functional exercise test)

You may not qualify if:

  • Patient with a contraindication to carrying out a respiratory rehabilitation program
  • Tracheostomized patient
  • Patient with a contraindication to the placement of a nasogastric tube
  • Pregnant or breastfeeding women or women of childbearing age without effective means of contraception (a pregnancy test will be carried out)
  • Protected adult patient (guardianship or curatorship)
  • Patient deprived of liberty by court or administrative decision
  • Refusal of patient participation or consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ADIR association

Bois-Guillaume, 76230, France

RECRUITING

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Officials

  • Elise ARTAUD-MACARI, MD

    ADIR Association

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: All patients were randomly allocated into two groups using the block randomization technique (blocks of eight patients) in a 1:1 ratio. In group A, a high-intensity constant work-rate endurance test using Venturi mask (VM) was performed on first, and a test using high-flow nasal canulae oxygen therapy (HFNC) was performed next. In group B, a high-intensity CWRET using HFNC was performed first, and a test using VM was performed next.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2022

First Posted

May 13, 2022

Study Start

November 22, 2022

Primary Completion

November 23, 2024

Study Completion

November 23, 2024

Last Updated

November 23, 2022

Record last verified: 2022-11

Locations